|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS: | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash equivalents | ||||||||||||||||||||
| Marketable securities, at fair value | ||||||||||||||||||||
| Restricted marketable securities, at fair value | ||||||||||||||||||||
| Accounts receivable, net (less allowances: $113,917 and $119,305) | ||||||||||||||||||||
| Notes receivable — short–term portion, net (less allowances: $$25,022 and $$25,931) | ||||||||||||||||||||
| Inventories and supplies | ||||||||||||||||||||
| Taxes receivable | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets (less accumulated amortization of $45,264 and $42,931) | ||||||||||||||||||||
| Notes receivable — long–term portion, net (less allowances: $2,924 and $1,776) | ||||||||||||||||||||
| Deferred compensation funding, at fair value | ||||||||||||||||||||
| Deferred tax assets | ||||||||||||||||||||
| Other long-term assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY: | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued payroll and related taxes | ||||||||||||||||||||
| Other accrued expenses and current liabilities | ||||||||||||||||||||
| Borrowings under line of credit | ||||||||||||||||||||
| Taxes payable | ||||||||||||||||||||
| Deferred compensation liability — short-term | ||||||||||||||||||||
| Accrued insurance claims | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Accrued insurance claims — long-term | ||||||||||||||||||||
| Deferred compensation liability — long-term | ||||||||||||||||||||
| Lease liability — long-term | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| STOCKHOLDERS’ EQUITY: | ||||||||||||||||||||
| Common stock, $0.01 par value; 200,000 shares authorized; 77,300 and 76,821 shares issued, and 67,432 and 69,596 shares outstanding | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss, net of taxes | ||||||||||||||||||||
| Common stock in treasury, at cost, 9,868 and 7,225 shares | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
| Common stock, authorized (in shares) | ||||||||||||||||||||
Loading...
